key: cord-0721134-fa4gt8nv
authors: Adamson, Paul C.; Goodman-Meza, David; Vijayan, Tara; Yang, Shangxin; Garner, Omai B.
title: Diagnostic yield of repeat testing for SARS-CoV-2: Experience from a large health system in Los Angeles
date: 2020-08-21
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.08.048
sha: 18c3f13beb5cac0e5fb9c26dec52f4cf8517a963
doc_id: 721134
cord_uid: fa4gt8nv

OBJECTIVE: To determine the diagnostic yield of repeat testing for SARS-CoV-2. METHODS: A retrospective analysis was performed of all SARS-CoV-2 test results within the UCLA Health System between March 9th and April 29th, 2020. All patients with repeat test results were identified and those with discordant results were reviewed. RESULTS: Between March 9th and April 29th there were 10,165 SARS-CoV-2 test results, of which 630 (6.2%) were positive. Among the 904 patients with repeat test results, 808 (89.4%) were initially negative and 96 (10.6%) were initially positive. Among the 808 patients with an initial negative test, 15 (1.9%) subsequently tested positive. Eleven cases with an initial negative SARS-CoV-2 test and without a known prior positive SARS-CoV-2 test were reviewed; 6 were employed as healthcare workers and 10 were positive on the second test. CONCLUSIONS: We found a low diagnostic yield of repeat testing for SARS-CoV-2 in our health system. Repeat testing might prove useful in certain clinical scenarios, such as in healthcare workers, when symptoms develop after a negative test, and in hospitalized patients with a high clinical suspicion for COVID-19.

In the United States, diagnostic testing capacity for SARS-CoV-2, the virus causing coronavirus disease 2019 , has increased (Adalja et al., 2020) . A key public health intervention to mitigate the spread of COVID-19 is timely testing for early diagnosis of infections (Pan et al., 2020) . Early in the epidemic, SARS-CoV-2 PCR testing was prioritized in clinical settings for symptomatic people who were: hospitalized, healthcare workers, or at high risk for complications (Centers for Disease Control and Prevention). Many diagnostic tests for SARS-CoV-2 have been developed and received Emergency Use Authorizations (EUA) by the U.S.

Food and Drug Administration (FDA). Yet, concerns exist about the clinical sensitivity and specificity of those tests, particularly with regard to the frequency of false negative test results, which might lead missed infections and ongoing transmission (Woloshin et al., 2020) .

Although repeat testing has been suggested as a way to increase diagnostic yield, there are sparse data on the yield of repeat testing (Lee et al., 2020 , Omer et al., 2020 . Moreover, repeat testing further limits supply and, among hospitalized patients, necessitates continued isolation and use of personal protective equipment, a limited commodity in the US (Livingston et al., 2020) . Therefore, it is of high importance for clinicians to understand the diagnostic yield of repeat testing for SARS-CoV-2. We aimed to provide insight into the diagnostic yield of repeat testing for SARS-CoV-2 within a large health system in Los Angeles, and highlight the clinical scenarios of discordant results in inidividuals with an initial negative test.

We reviewed all SARS-CoV-2 tests within the UCLA Health System collected between March 9 th and April 29th, 2020. Nasopharyngeal specimens were the preferred specimen collection method at our institution. During the time period of the study, nasal and oropharyngeal swabs were not used. For inpatients with concern for lower respiratory tract disease, clinicians could order lower respiratory tract specimens (e.g.expectorated sputum, bronchoalveolar lavage (BAL), tracheal aspirate). RNA in upper and lower respiratory specimens. Each specimen submitted for testing was tested using only one of the aforementioned diagnostic assays.

We defined multiple tests performed within the same patient as repeat tests. We excluded cases where the initial test was inconclusive. We report total number of tests, overall test positivity, and the number of patients with repeat tests and discordant results.

In total, there were 10,165 SARS-CoV-2 tests performed and 6.2% (630/10,165) were positive. There were 906 patients with repeat test results, 2 were excluded due to inconclusive initial results. Among the 904 total cases, 808 (89.4%) were initially negative and 96 (10.6%) were initially positive. Those 904 patients accounted for 2,108 tests with an overall positivity of 9.9% (n = 209). The vast majority (93.7%) of those tests were performed on nasopharyngeal specimens and 65% were performed on the Diasorin platform. The number of tests and SARS-CoV-2 positivity by diagnostic assay and specimen type are shown in Table 1 .

Among the 96 patients with initial positive tests, 56 (58.3%) were repeated once, 24 (25.0%) were repeated twice, eight (8.3%) were repeated thrice, and eight (8.3%) were repeated four or more times. Repeat testing among positive cases was often done for infection control practices and for discharge planning. Among those with an initial positive test, 50% had a subsequent negative result (48/96); the median time between positive and negative tests was 16 days (interquartile range: 9 -27 days). (Figure 1 , Panel A) Among the 808 patients with an initial negative test, 646 (80.0%) were repeated once, 110 (13.6%) repeated twice, 39 (4.8%) were repeated thrice, and 13 (1.6%) were repeated four times; fifteen (1.9%) subsequently tested positive. (Figure 1 , Panel B) Clinical information was not available for one case. In three instances, patients were transferred from an outside facility where they had a positive SARS-COV-2 test. All transferred patients had an negative test on arrival, but a subsequent positive test within 24 hours.

There were 11 cases with an initial negative SARS-CoV-2 test, without a known prior positive SARS-CoV-2 test, and with reasons for repeat testing available for review. All of the initial tests were done on nasopharyngeal specimens and ten of the cases tested positive the second time. Six individuals with an initial negative test and a subsequent positive test were employed as healthcare workers (HCWs). The clinical scenarios for testing, as well as the specimen type, setting, diagnostic assay, and possible reasons for the initial negative result are presented in Table 2 . Testing prior to infection was likely in one case, as there were 20 days between the negative test and the development of symptoms. In three cases, pre-symptomatic testing was the likely explanation, as symptoms of acute illness developed after the initial test.

In the remaining cases, possible reasons for the initial negative test result were inadequate specimen collection or inconsistent viral shedding.

We found that repeat testing for SARS-CoV-2 had low diagnostic yield. Discordant results occurred in only 1.3% of patients with an initial negative test and without a prior J o u r n a l P r e -p r o o f diagnosis of SARS-CoV-2 infection. Consideration of the pretest probability alongside the estimated test performance can be used to guide repeat testing (Woloshin et al., 2020) . For example, our report highlighted that repeat testing might prove useful in HCWs with ongoing exposures, as over half of those with initial negative tests and a subsequent positive test were employed as HCWs.

Other scenarios where repeat testing after a negative test might be useful include when symptoms of COVID-19 develop after a negative test, if inadequate specimen collection is suspected, and in hospitalized patients with high clinical suspicion for COVID-19 (Lee et al., 2020) . Moreover, public health interventions to mitigate the spread of COVID-19 rely on timely testing and early diagnosis of infections, in order to inform isolation, contact tracing, and quarantine efforts, and repeat testing will be needed in these situations (Pan et al., 2020) .

SARS-CoV-2 viral shedding can be variable and the timing related to exposure and symptom onset is important to test result interpretation (Wölfel et al., 2020 , Zou et al., 2020 .

Available data suggest SARS-CoV-2 is typically detectable by RT-PCR in the nasopharynx by symptom onset and that viral loads are highest in the nasopharynx in the first week of the infectious course (Sethuraman et al., 2020 , Wölfel et al., 2020 , Zou et al., 2020 . In our report, testing prior to infection was the likely explanation in one case and testing prior to symptom onset appeared to be the reason for three cases. In most cases, it was not possible to differentiate between variability in viral shedding and poor specimen collection. While the timing and quality of specimen collection are key, a false negative test result is still possible. Data regarding the clinical sensitivity remain quite limited. Preliminary reports suggest that nasopharyngeal specimens might have up to 27% false negativity and a systematic review estimated false negatives in 2% to 29% of specimens, although the quality of evidence was low (Arevalo-Rodriguez et al., 2020 , Yang et al., 2020 .

Retesting positive cases was recommended as a way to document viral clearance and remove isolation precautions (Centers for Disease Control and Prevention). In our report, J o u r n a l P r e -p r o o f approximately half of those with an initial positive test had a subsequent negative test. Prior reports have documented prolonged duration of SARS-CoV-2 positivity by RT-PCR, up to 6 weeks in some cases (Lan et al., 2020 , Qi et al., 2020 , Zhou et al., 2020 . RT-PCR tests are characteristically sensitive, but are unable to discriminate between the presence of replicating virus and non-infectious remnants that contain nucleic acid targets. However, emerging evidence now suggests there is very low likelihood of infectivity, as measured by culturing viable SARS-CoV-2, if more than 8 days has elapsed since time of symptom onset (Bullard et al., 2020 , Wölfel et al., 2020 .

Our results should be considered in light of the following limitations. First, our study was performed within one health system and might not be generalizable to other settings. The report highlighted instances where repeat testing yielded discordant results in a clinical setting and might not be generalizable to repeat testing as part of a broader public health response.

Second, we could not assess differences in tests by anatomic site, as we did not have paired specimens. Nevertheless, we provided data on repeat testing for SARS-CoV-2 within a large health system and highlighted cases where repeat testing improved diagnostic yield. In a clinical setting, repeat testing can be considered based on changes to clinical status and the pre-test probability of infection.

Funding: This work was supported by the National Institutes for Health (P.C.A. is supported by grant number T32MH080634 and D. G. is supported by grant number K08DA048163).

The retrospective analysis was undertaken as a quality assurance project and did not meet research criteria for review by our institutional review board.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Tracheal specimen 3 (30.0) 10

Other 0 (0) 5 

Priorities for the US Health Community Responding to COVID-19

Predicting infectious SARS-CoV-2 from diagnostic samples

COVID-19) -Discharging Hospitalized Patients

Simplex COVID-19 Direct real-time RT-PCR assay

Positive RT-PCR Test Results in Patients Recovered From COVID-19

Testing for SARS-CoV-2: Can We Stop at Two? Clinical Infectious Diseases

Sourcing Personal Protective Equipment During the COVID-19 Pandemic

The COVID-19 Pandemic in the US

Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China

Factors associated with the duration of viral shedding in adults with COVID-19 outside of Wuhan, China: a retrospective cohort study

SARS-CoV-2 RNA Qualitative Real-Time RT-PCR

Interpreting Diagnostic Tests for SARS-CoV-2

ThermoFisher Scientific. TaqPath COVID-19 Combo Kit

Virological assessment of hospitalized patients with COVID-2019

False Negative Tests for SARS-CoV-2 Infection -Challenges and Implications

Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections

Duration of Viral Shedding of Discharged Patients With Severe COVID-19

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients